** Medical device maker’s shares up 8 pct at $11.74
** Receives Health Canada’s approval for retinal implants to treat patients with outer retinal degeneration
** Company’s Argus II Retinal Prosthesis is an electronic implant designed to improve vision in those with severe cases of the inherited disease
** Outer retinal degeneration is caused by progressive death of the cells in the region
** Argus II Retinal Prosthesis already approved in U.S.
** Up to Friday’s close, stock had risen 20 pct since its debut on Nov. 19